Prior to the issuance of new shares of series B, there were in total 8,068,000 shares in Elos Medtech, of which 1,099,740 shares of series A, corresponding to an equal number of votes, and 6,968,260 shares of series B, corresponding to 696,826 votes, corresponding to 1,796,566 votes in total.

Through the rights issue, the number of shares of series B has increased by 20,170,000, corresponding to 2,017,000 votes. As of 30 November 2023, there are in total 28,238,000 shares in Elos Medtech, of which 1,099,740 shares of series A, corresponding to an equal number of votes, and 27,138,260 shares of series B, corresponding to 2,713,826 votes, corresponding to 3,813,566 votes in total.

For further information, please contact:

Stefano Alfonsi, President and CEO, +44 772 04 98 342, email: stefano.alfonsi@elosmedtech.com
Ewa Linsäter, CFO, +46 766 33 32 33, email: ewa.linsater@elosmedtech.com

About Elos Medtech
Elos Medtech is a leading development and production partner for medical devices and components, with a focus on dental and orthopedic implants and instruments. The Company operates from facilities in Sweden, Denmark, China, and the U.S. The customer base comprises international medical technology companies.

Elos Medtech has more than 650 employees and a turnover of approximately SEK 950 million. Elos Medtech has been listed on NASDAQ Stockholm AB since 1989. Elos Medtech's B share is categorized as a Health Care company on the Mid Cap list.

Elos Medtech discloses the information herein pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 (CET) on 30 November 2023.